Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Blueberry Therapeutics

Request full access

Topical nanomedicines for treating dermatological conditions

Macclesfield, United KingdomFounded 2011Biotech & Life Sciences

About Blueberry Therapeutics

Blueberry Therapeutics is a drug discovery and development company founded in 2011 by Michael John Davies and headquartered in Alderley Edge, United Kingdom. The company concentrates on creating topical nanomedicines for dermatological conditions, particularly infectious and inflammatory diseases of the skin and nail. Its primary business model involves using a proprietary nanopolymer drug delivery system, called Nanocin™, to enhance the delivery of existing drugs into the skin and nails. This approach aims to improve efficacy and safety, allowing for lower doses and shorter treatment durations compared to existing oral or topical treatments.

The company's lead product candidate, BB2603, is a topical nano-formulation of the antifungal drug terbinafine, delivered as a spray to treat onychomycosis (fungal nail infection) and tinea pedis (athlete's foot). In November 2023, Blueberry announced that its Phase 2b clinical trial for BB2603 met its primary and secondary endpoints, showing significant effectiveness after just three months of treatment. The company is also developing treatments for other conditions such as acne and atopic dermatitis.

Blueberry Therapeutics has raised a total of $23.8 million over five funding rounds since its first round in 2015. Key investors include China Medical System, Medical Incubator Japan, Maven Capital Partners, and the GM&C Life Sciences Fund. The funding has supported the clinical development of its product pipeline, with plans to advance BB2603 into Phase 3 trials in the US and EU. According to a filing in April 2024, the company was reported as out of business due to bankruptcy and liquidation.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
60.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Skin Care, Dermatology, Arts & Culture, Biotech and Pharma, DT and LS, rio ai health
Technology
Nanotech
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jun 2021 $990K $66M Northern Powerhouse Investment Fund —
SERIES B✓Equity / VC Feb 2021 $4.8M $66M Medical Incubator Japan · Omar Ibrahimi —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Blueberry Therapeutics website traffic

Latest recorded traffic for Blueberry Therapeutics is 210 monthly website visits, down 88.3% over the last three months. Blueberry Therapeutics's team grew 0% over the past year.

Latest monthly visits210 3-month web change-88.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Blueberry Therapeutics in the Macclesfield ecosystem

Live from Dealroom

The Blueberry Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • SBRI Healthcare

Series A3 investors entered at this stage

  • GM&C Life Sciences Fund
  • Medical Incubator Japan
  • Omar Ibrahimi

Series B and later2 investors entered at this stage

  • China Medical System Holdings
  • Northern Powerhouse Investment Fund

Other known investors1 additional known investor

  • GC Angels
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Blueberry Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Blueberry Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.